The 4th Paris NASH Meeting was held July 5-6, 2018 at the Institut Pasteur in Paris, France. The meeting was co-organizated by Dr. Lawrence Serfaty, Hôpitaux Universitaires de Strasbourg, Dr. Arun Sanyal, Virginia Commonwealth University, and Dr. Veronica Miller, Forum for Collaborative Research
The materials from the 2-day meeting that have been made available can be found on the meeting website (https://paris-nash.org/materials), or below:
THURSDAY, JULY 5, 2018
- Welcome remarks
Lawrence Serfaty (France) - Inauguration Address
Stanislas Pol (France)
SESSION 1 • NASH EPIDEMIOLOGY AND PUBLIC HEALTH
Chairs: Patrick Marcellin (France) and Michael Trauner (Austria)
- The value proposition of NASH therapy on the burden of disease related to obesity.
Homie Razavi (USA) - The evolution of NASH from childhood to adulthood.
Joel Lavine (USA) - What is needed to put NASH on the radar for WHO- lessons learned from viral hepatitis.
Jean-Michel Pawlotsky (France) and Stanislas Pol (France) - Discussion
SESSION 2 • CARDIO-METABOLIC MORBIDITY AND MORTALITY DUE TO NAFLD
Chairs: Scott Friedman (USA) and Fabio Marra (Italy)
- Does reversal of NASH reverse cardiovascular risk?
Bart Staels (France) - Is type 2 diabetes and NASH the same disease affecting different organs?
Bertrand Cariou (France) - Acceleration of cardiometabolic disease after liver transplantation for NASH.
Mohammad Siddiqui (USA) - Discussion
SESSION 3 • CLINICAL STATE OF THE ART LECTURE
Chair: Philippe Mathurin (France)
- The pathophysiological, clinical and regulatory implications of alcohol consumption in Non Alcoholic SteatoHepatitis.
Arun Sanyal (USA)
SESSION 4 • PRECISION MEDICINE FOR NASH
Chairs: Quentin Anstee (United Kingdom) and Lawrence Serfaty (France)
- Molecular markers of disease progression in NASH.
Jean-François Dufour (Switzerland) - Phenotyping NAFLD based on whole body morphometry.
Olof Dahlqvist Leinhard (Sweden) - Phenotyping NAFLD based on the gut microbiome.
Karim Dabbagh (USA) - The potential use of iPSC to guide Precision Medicine for NASH.
David Goldman (USA) - Discussion
SESSION 5 • TECHNOLOGIC INNOVATIONS IN NASH
Chairs: Jean-Pierre Bronowicki (France) and Frank Tacke (Germany)
- Radiomics and imaging inflammation in solid organs.
Richard Ehman (USA) - The protease signature of NASH.
Gabe Kwong (USA) - Gut-based immunotherapy - implications for NASH.
Yaron Ilan (Israel) - Discussion
FRIDAY, JULY 6, 2018
SESSION 6 • NAFLD AND HCC
Chairs: Stanislas Pol (France) and Manuel Romero-Gómez (Spain)
- Clinical and Pathological characteristics of steatohepatitis HCC.
Pierre Bedossa (France) - Immune mechanisms in the genesis of HCC due to NASH.
Frank Tacke (Germany) - Epigenetic basis for NASH associated HCC.
Igor Pogribny (USA) - How will new therapies affect HCC development?
Scott Friedman (USA) - Discussion
SESSION 7 • PATIENT CENTERED APPROACH TO NASH
Chairs: Mohammad Siddiqui (USA) and Zobair Younossi (USA)
- Development of a patient reported outcomes instrument for NASH that meets regulatory standards.
Maria-Magdalena Balp (Switzerland) - The science and art of patient-engaged trial design.
Donna Cryer (USA) - The burden of cirrhosis on their caregivers.
Jasmohan Bajaj (USA) - Discussion
SESSION 8 • REGULATORY LANDSCAPE
Chair: Lawrence Serfaty (France)
- Regulatory Update.
Veronica Miller (USA) - Discussion
SESSION 9 • TRIAL DESIGN
Chairs: Veronica Miller (USA) and Arun Sanyal (USA)
- Master - protocols in NASH - challenges and opportunities.
Raluca Pais (France) - Learning from placebo responses in current trials to improve future trial design.
Quentin Anstee (United Kingdom) - Discussion
SESSION 10 • ROUND TABLE
Chairs: Arun Sanyal (USA) and Lawrence Serfaty (France)
- Building synergy between patient advocacy and drug development for NASH.
Panelists: Quentin Anstee (United Kingdom), Donna Cryer (USA), Dean Hum (France), Omoro Omoighe (USA), Manuel Romero-Gómez (Spain), Aldo Trylesinski (United Kingdom), Marko Korenjak (Slovenia)